Analyst Estimates: Here's What Brokers Think Of Medacta Group SA (VTX:MOVE) After Its Half-Yearly Report
Medacta Group SA (VTX:MOVE) shareholders are probably feeling a little disappointed, since its shares fell 9.8% to CHF114 in the week after its latest interim results. Results were roughly in line with estimates, with revenues of €368m and statutory earnings per share of €4.78. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Following the latest results, Medacta Group's five analysts are now forecasting revenues of €763.6m in 2026. This would be a credible 7.9% improvement in revenue compared to the last 12 months. Per-share earnings are expected to jump 30% to €5.05. Before this earnings report, the analysts had been forecasting revenues of €765.4m and earnings per share (EPS) of €5.28 in 2026. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.
See our latest analysis for Medacta Group
It might be a surprise to learn that the consensus price target was broadly unchanged at CHF178, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Medacta Group at CHF193 per share, while the most bearish prices it at CHF152. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 16% growth on an annualised basis. That is in line with its 15% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 7.1% annually. So it's pretty clear that Medacta Group is forecast to grow substantially faster than its industry.
The Bottom Line
The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at CHF178, with the latest estimates not enough to have an impact on their price targets.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Medacta Group going out to 2028, and you can see them free on our platform here.
Even so, be aware that Medacta Group is showing 1 warning sign in our investment analysis , you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.